- Chardan Capital downgraded Tenax Therapeutics to a Neutral rating following recent clinical trial results.
- The Phase III LEVEL trial for oral levosimendan (TNX-103) did not meet its primary endpoint for overall patient improvement.
- Despite the primary endpoint miss, positive findings were observed in a specific patient subgroup (aged 74 and older) and a key biomarker reduction.
Tenax Therapeutics (NASDAQ:TENX) is a pharmaceutical company that develops and commercializes products for cardiovascular and pulmonary diseases. The company’s main focus is on its experimental drug, oral levosimendan (TNX-103). This drug is intended to treat pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a serious heart and lung condition, highlighting its commitment to biotechnology and drug development.
On August 11, 2026, an analyst from Chardan Capital set a new price target of $5.00 for Tenax Therapeutics, as published by TheFly. A price target is an analyst’s projection of a stock’s future price, offering investment insights. At the time, the stock was trading at $1.64 per share, suggesting the analyst sees potential for future growth in the healthcare sector.
This update was associated with Chardan Capital downgrading Tenax Therapeutics to a Neutral rating from its previous Buy rating. This downgrade follows the company’s announcement that its Phase III LEVEL trial for levosimendan did not meet its primary endpoint, which was a key measure of the drug’s effectiveness.
The trial’s goal was to show a significant improvement in the distance patients could walk in six minutes. While patients on the drug improved by 14 meters, this was not statistically significant compared to the 10.4-meter improvement in the placebo group. A result that is not statistically significant means it could have happened by chance.
Despite the trial’s main outcome, the company reported some positive findings, as highlighted by GlobeNewswire. A specific group of patients aged 74 and older showed a 37.6-meter improvement in walk distance. The company also noted a 49% greater reduction in a key biomarker, NT-proBNP, compared to the placebo.
